Naomi Lowy

Where Does Rare Disease And Patient-Focus Fall Into Commissioner Makary's Priorities & The MAHA Platform For FDA? A New Ultrarare Approval Pathway & More

More Uncertainty And Less Advice From FDA Means Companies Will Need To Even More Carefully Chart Their Own Course To Achieve Their Goals